FDA Advisory Panel Backs BPC-157 for 503A Bulks List in 8-6-1 Vote, Promise Analysis Finds

The July 2026 recommendation is non-binding and does not make BPC-157 FDA-approved; FDA staff proposed against inclusion, while a 2025 systematic review found 35 preclinical studies and one clinical study in scope. SCOTTSDALE, Ariz., Sept. 8, 2026 /PRNewswire/ -- A July 2026 vote by the...